I 

118TH CONGRESS 

1ST SESSION H. R. 6674 

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 7, 2023 

Mr. KILDEE (for himself and Mr. LAWLER) introduced the following bill; 

which was referred to the Committee on Energy and Commerce 

A BILL 

To provide for the periodic issuance of up-to-date clinical 

guidance on addressing the health effects of per- and 

polyfluoroalkyl substances (PFAS), and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Better Care for PFAS 

5 Patients Act of 2023’’. 


ddrumheller on DSK120RN23PROD with BILLS
2 

•HR 6674 IH

1 SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, REC2 OMMENDATIONS, AND GUIDANCE. 

3 (a) PERIODIC ASSESSMENT AND RECOMMENDA4 TIONS.— 

5 (1) AGREEMENT.—The Director of the Agency 

6 for Toxic Substances and Disease Registry (in this 

7 section referred to as the ‘‘Director’’) shall enter 

8 into an agreement with the National Academies of 

9 Sciences, Engineering, and Medicine (or another ap10 propriate entity if the National Academies declines 

11 to enter into such agreement) under which the Na12 tional Academies or the other appropriate entity 

13 agrees— 

14 (A) to assess the health effects of per- and 

15 polyfluoroalkyl substances (in this section re16 ferred to as ‘‘PFAS’’) that can be measured in 

17 human tissues; 

18 (B) to formulate clinical recommendations 

19 on addressing such health effects; 

20 (C) not later than 2 years after the date 

21 of entry into such agreement, to complete the 

22 initial assessment under subparagraph (A) and 

23 formulate the initial recommendations under 

24 subparagraph (B); and 

25 (D) to update the most recent assessment 

26 and recommendations under this paragraph— 


ddrumheller on DSK120RN23PROD with BILLS
3 

•HR 6674 IH

1 (i) every 5 years; or 

2 (ii) more frequently as determined 

3 necessary by the Director based on an as4 sessment of the science. 

5 (2) TIMING OF ENTRY INTO AGREEMENT.—The 

6 Director shall enter into the agreement required by 

7 paragraph (1) not later than 60 days after the date 

8 of enactment of this Act. 

9 (b) UP-TO-DATE GUIDANCE.—Based on the results 

10 of the most recent assessment and recommendations 

11 under subsection (a), the Director, in consultation with 

12 the entity with which the Director enters into the agree13 ment under subsection (a), shall— 

14 (1) not later than 5 years after the date of 

15 entry into the agreement required by subsection 

16 (a)— 

17 (A) issue up-to-date clinical guidance on 

18 addressing the health effects of PFAS; 

19 (B) post such guidance on the public 

20 website of the Agency for Toxic Substances and 

21 Disease Registry; and 

22 (C) disseminate such guidance to State 

23 and local public health authorities and appro24 priate health care professionals; and 


ddrumheller on DSK120RN23PROD with BILLS
4 

•HR 6674 IH

1 (2) every 5 years thereafter, or more frequently 

2 as determined necessary by the Director based on an 

3 assessment of the science, issue, post, and dissemi4 nate up-to-date guidance as described in paragraph 

5 (1). 

Æ 


ddrumheller on DSK120RN23PROD with BILLS